

NEW DRUGS

A:

ANSWERS  
TO SELF-TEST  
QUESTIONS

- |         |         |
|---------|---------|
| 1 False | 2 True  |
| 3 False | 4 False |
| 5 False | 6 True  |

- Paul C, Lacour JP, Tedremets L, Kreutzer K, Jazayeri S, Adams S, et al.; JUNCTURE study group. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). *J Eur Acad Dermatol Venereol* 2015;29:1082-90. <http://dx.doi.org/10.1111/jdv.12751>
- Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. *J Am Acad Dermatol* 2015;73:400-9. <http://dx.doi.org/10.1016/j.jaad.2015.05.013>

The Transparency score (T) is explained in 'New drugs: transparency', *Aust Prescr* 2014;37:27.

- \* At the time the comment was prepared, information about this drug was available on the website of the Food and Drug Administration in the USA ([www.fda.gov](http://www.fda.gov)).
- † At the time the comment was prepared, a scientific discussion about this drug was available on the website of the European Medicines Agency ([www.ema.europa.eu](http://www.ema.europa.eu)).
- <sup>A</sup> At the time the comment was prepared, information about this drug was available on the website of the Therapeutic Goods Administration ([www.tga.gov.au/industry/pm-auspar.htm](http://www.tga.gov.au/industry/pm-auspar.htm)).

Correction

How to manage warfarin therapy

*Aust Prescr* 2015;38:44-8

In the section on 'Maintenance therapy', the phrase 'and some complementary medicines such as St John's wort' has been removed from the list of drugs that may increase INR, because St John's wort decreases INR.

© NPS MedicineWise  
ABN 61 082 034 393

NPS MedicineWise Disclaimer

Reasonable care is taken to provide accurate information at the time of creation. This information is not intended as a substitute for medical advice and should not be exclusively relied on to manage or diagnose a medical condition. NPS MedicineWise disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information.

SUBSCRIPTIONS

*Australian Prescriber* is published every two months online. All content is accessible free of charge in full text at [nps.org.au/australianprescriber](http://nps.org.au/australianprescriber). New drugs are published between issues as they become available.

An email alert can be sent to you when *Australian Prescriber* publishes new material. Subscribe or update your details at [nps.org.au/australianprescriber](http://nps.org.au/australianprescriber)

For back issues and copies of the Anaphylaxis wallchart, email [info@australianprescriber.com](mailto:info@australianprescriber.com)

EDITORIAL OFFICE

For general correspondence such as Letters to the Editor, contact the Editor.

Postal The Editor  
*Australian Prescriber*  
PO Box 104  
DEAKIN WEST 2600

Telephone (02) 6202 3100

Fax (02) 6282 6855

Email [info@australianprescriber.com](mailto:info@australianprescriber.com)

Website [nps.org.au/australianprescriber](http://nps.org.au/australianprescriber)

Twitter @AustPrescriber